High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes

Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected...

Full description

Bibliographic Details
Main Authors: Matthew R. Gardner, Desiree E. Mendes, Claudia P. Muniz, José M. Martinez-Navio, Sebastian P. Fuchs, Guangping Gao, Ronald C. Desrosiers
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050122000043